7 research outputs found
Butterfly surveys in Albania during 2014 including the discovery of two new species for the country
During field surveys conducted in Albania in 2014, we encountered 90 species of butterflies. Anthocharis damone Boisduval, 1836 is a new species for the fauna of Albania while Apatura metis Freyer, 1829 is confirmed for the country. With these discoveries the number of butterfly species known to occur in Albania has risen to 200 and our surveys added many new sites for species considered rare and local in Albania. In addition, the life cycles of Lycaena ottomana (Lefèbvre, 1830) and Apatura metis from Albania are documented and discussed
Confirmation du status spécifique de Polyommatus gennargenti (Leigheb, 1987) de Sardaigne comparé à Polyommatus coridon (Poda, 1761) de la région de Schaffhousen (CH) par élevage parrallèle (Lepidoptera: Lycaenidae) 1ère partie
Confirmation du status spécifique de Polyommatus gennargenti (Leigheb, 1987) de Sardaigne comparé à Polyommatus coridon (Poda, 1761) de la région de Schaffhousen (CH) par élevage parrallèle (Lepidoptera: Lycaenidae) 1ère partie
Botulinum toxin a for nonambulatory children with cerebral palsy: A double blind randomized controlled trial
Objectives: To examine the efficacy and safety of intramuscular botulinum toxin A (BoNT-A) to reduce spasticity and improve comfort and ease of care in nonambulant children with cerebral palsy (CP). Study design: Nonambulant children with CP (n = 41; Gross Motor Function Classification System level IV = 3, level V = 38; mean age 7.1 years, range 2.3-16 years, 66% male) were randomly allocated to receive either intramuscular BoNT-A injections (n = 23) or sham procedure (n = 18) combined with therapy. The analysis used generalized estimating equations with primary outcome the Canadian Occupational Performance Measure (COPM) at 4 weeks postintervention and retention of effects at 16 weeks. Adverse events (AE) were collected at 2, 4, and 16 weeks by a physician masked to group allocation. Results: There were significant between group differences favoring the BoNT-A-treated group on COPM performance at 4 weeks (estimated mean difference 2.2, 95% CI 0.8, 3.5; P = .002) and for COPM satisfaction (estimated mean difference 2.2, 95% CI 0.5, 3.9; P = .01). These effects were retained at 16 weeks for COPM satisfaction (estimated mean difference 1.8, 95% CI 0.1, 3.5; P = .04). There were more mild AE at 4 weeks for the BoNT-A group (P = .002), however, there were no significant between-group differences in the reporting of moderate and serious AE. Conclusions: In a double-blind randomized sham-controlled trial, intramuscular BoNT-A and therapy were effective for improving ease of care and comfort for nonambulant children with CP. There was no increase in moderate and severe AE in the children who had BoNT-A injections compared with the sham group
Evaluation of the effects of Botulinum toxin A injections when used to improve ease of care and comfort in children with cerebral palsy whom are non-ambulant: A double blind randomized controlled trial
Background: Children with cerebral palsy (CP) whom are non-ambulant are at risk of reduced quality of life and poor health status. Severe spasticity leads to discomfort and pain. Carer burden for families is significant. This study aims to determine whether intramuscular injections of botulinum toxin A (BoNT-A) combined with a regime of standard therapy has a positive effect on care and comfort for children with CP whom are non-ambulant (GMFCS IV/V), compared with standard therapy alone (cycle I), and whether repeated injections with the same regime of adjunctive therapy results in greater benefits compared with a single injecting episode (cycle II). The regime of therapy will include serial casting, splinting and/or provision of orthoses, as indicated, combined with four sessions of goal directed occupational therapy or physiotherapy